ASCO China Perspective | Juliang Zhang: I-SPY 2.2 Highlights the Potential of Bispecific Immunotherapy Plus T-DXd and Novel Immune Subtyping in HER2-Negative Breast Cancer

ASCO China Perspective | Juliang Zhang: I-SPY 2.2 Highlights the Potential of Bispecific Immunotherapy Plus T-DXd and Novel Immune Subtyping in HER2-Negative Breast Cancer

Neoadjuvant treatment for operable HER2-negative breast cancer remains a major clinical challenge. The emergence of antibody-drug conjugates (ADCs), particularly trastuzumab deruxtecan (T-DXd), is reshaping traditional treatment paradigms while raising new questions about patient selection and optimal therapeutic strategies.
ASCO China Perspective | Jin Yang: lidERA BC Suggests Oral SERDs Could Reshape Adjuvant Therapy for High-Risk Premenopausal Breast Cancer

ASCO China Perspective | Jin Yang: lidERA BC Suggests Oral SERDs Could Reshape Adjuvant Therapy for High-Risk Premenopausal Breast Cancer

At ASCO 2026, investigators presented the pre-specified menopausal subgroup analysis from the lidERA BC trial. Compared with standard endocrine therapy, the oral selective estrogen receptor degrader (SERD) giredestrant reduced the risk of distant recurrence by 42% in premenopausal women with HR+/HER2− early breast cancer (HR=0.58), while also reducing the risk by 24% in postmenopausal patients (HR=0.76). These findings offer renewed optimism for adjuvant endocrine therapy, an area that has seen few major advances over the past decade.
ASCO China Voice | Zhenzhen Liu: HELEN Series Studies Presented at ASCO Advance Precision Treatment Strategies for Breast Cancer

ASCO China Voice | Zhenzhen Liu: HELEN Series Studies Presented at ASCO Advance Precision Treatment Strategies for Breast Cancer

At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Zhenzhen Liu and colleagues from Henan Cancer Hospital presented four studies from the HELEN clinical research program (Abstracts #1009, #509, #1054, and #609), spanning key breast cancer subtypes including triple-negative breast cancer (TNBC), HER2-positive disease, and HR+/HER2+ breast cancer.
ASCO China Voice | Xiaowei Qi: Pembrolizumab-Free Anthracycline-Sparing Neoadjuvant Regimen with Penpulimab, Taxane, and Carboplatin Demonstrates Promising Efficacy and Safety in Triple-Negative Breast Cancer

ASCO China Voice | Xiaowei Qi: Pembrolizumab-Free Anthracycline-Sparing Neoadjuvant Regimen with Penpulimab, Taxane, and Carboplatin Demonstrates Promising Efficacy and Safety in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive disease with a poor prognosis, making it essential to improve the efficacy of neoadjuvant therapy while minimizing treatment-related toxicity. At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Xiaowei Qi and colleagues from Southwest Hospital, Army Medical University presented the latest results from the NeoTAPPL study (Abstract #600).
ASCO China Voice | Zhimin Shao and Zhonghua Wang’s Team: IRIS-A Study Demonstrates That Capecitabine Plus Trastuzumab Provides Effective, Low-Toxicity De-escalated Adjuvant Therapy for Stage IA HER2-Positive Breast Cancer

ASCO China Voice | Zhimin Shao and Zhonghua Wang’s Team: IRIS-A Study Demonstrates That Capecitabine Plus Trastuzumab Provides Effective, Low-Toxicity De-escalated Adjuvant Therapy for Stage IA HER2-Positive Breast Cancer

At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, held from May 29 to June 2 in Chicago, USA, results from the IRIS-A study (Abstract #508) were presented during the Rapid Oral Abstract Session on Local, Regional, and Adjuvant Breast Cancer.
ASCO China Voice | Professor Hui Xie: BMI May Serve as a Simple Stratification Marker for Trastuzumab Deruxtecan in Advanced Breast Cancer

ASCO China Voice | Professor Hui Xie: BMI May Serve as a Simple Stratification Marker for Trastuzumab Deruxtecan in Advanced Breast Cancer

At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, a study led by Professor Hui Xie from Jiangsu Cancer Hospital was presented as an electronic poster (Abstract e13078). Using multicenter real-world data from China, the study is the first to systematically evaluate the relationship between body mass index (BMI) and the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2-positive or HER2-low advanced breast cancer.
ASCO China Voice | Academician Binghe Xu: China-Developed B7-H4 ADC Demonstrates Promising Antitumor Activity and Excellent Safety, Offering a Potential Breakthrough for Two Difficult-to-Treat Advanced Solid Tumors

ASCO China Voice | Academician Binghe Xu: China-Developed B7-H4 ADC Demonstrates Promising Antitumor Activity and Excellent Safety, Offering a Potential Breakthrough for Two Difficult-to-Treat Advanced Solid Tumors

The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, held from May 29 to June 2 in Chicago, USA, featured the first-in-human Phase 1a results (Abstract #3013) of BG-C9074, a novel B7-H4-targeting antibody-drug conjugate (ADC) developed in China, during the Rapid Oral Abstract Session on Developmental Therapeutics.
ASCO China Voice | Professors Jian Zhang and Wenxing Qin: Chinese-Developed Oral SERD TFX06 Demonstrates Promising Activity in Fulvestrant-Pretreated ER+/HER2− Advanced Breast Cancer

ASCO China Voice | Professors Jian Zhang and Wenxing Qin: Chinese-Developed Oral SERD TFX06 Demonstrates Promising Activity in Fulvestrant-Pretreated ER+/HER2− Advanced Breast Cancer

For patients with HR+/HER2− advanced breast cancer, fulvestrant combined with targeted therapy remains the preferred treatment after progression on aromatase inhibitors (AIs). However, for patients whose disease progresses following fulvestrant, there is currently no established standard of care worldwide.